ClinicalTrials.Veeva

Find clinical trials for Lymphoma in New Haven, CT

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

B-Cell Lymphoma
Leukemia
Non-Hodgkin Lymphoma
Lymphoid Leukemia
Diffuse Large B-Cell Lymphoma
Precursor Cell Lymphoblastic Leukemia-Lymphoma
B-Cell Chronic Lymphocytic Leukemia

Lymphoma trials near New Haven, CT, USA:

RITUXIMAB + IMMUNOTHERAPY IN FOLLICULAR LYMPHOMA

This research study is studying several new investigational drug combinations as a possible treatment for follicular lymphoma.The drugs invo...

Active, not recruiting
Follicular Lymphoma
Drug: Avelumab
Drug: PF04518600

Phase 1

Dana-Farber Cancer Institute
Dana-Farber Cancer Institute

New Haven, Connecticut, United States and 5 other locations

in subjects with relapsed/refractory CD30 positive T-cell lymphoma (including peripheral T-cell lymphoma and cutaneous T-cell lymphoma...

Enrolling
T-Cell Lymphoma
Drug: Brentuximab vedotin
Drug: Pembrolizumab

Phase 2

Sethi

New Haven, Connecticut, United States

DS-3201b is an experimental drug. It is not approved for regular use. It can only be used in clinical research.Adults with non-Hodgkin lymphoma...

Active, not recruiting
Lymphoma, Malignant
Non-hodgkin Lymphoma
Drug: DS-3201b

Phase 1

Daiichi Sankyo
Daiichi Sankyo

New Haven, Connecticut, United States and 20 other locations

diagnosed or relapsed/refractory (for CTCL only) aggressive T cell lymphoma including patients with Adult T-cell leukemia/lymphoma ...

Begins enrollment in 1 month
T Cell Lymphoma
Drug: Mogamulizumab
Drug: DA-EPOCH Protocol

Phase 2

Yale University
Yale University

New Haven, Connecticut, United States

Part 1: To characterize the safety profile of acalabrutinib alone or in combination with rituximab in subjects with R/R FL.Part 2: To characterize th...

Active, not recruiting
Non Hodgkin Lymphoma
Drug: acalabrutinib
Drug: rituximab (IV)

Phase 1

Acerta Pharma
Acerta Pharma

Hawthorne, New York, United States and 31 other locations

Locations recently updated

focused on patients who have one of two types of cancer: follicular lymphoma (FL) or marginal zone lymphoma (MZL) that has come bac...

Enrolling
Marginal Zone Lymphoma (MZL)
Relapsed/Refractory Follicular Lymphoma
Drug: Rituximab
Drug: Lenalidomide

Phase 3

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Stony Brook, New York, United States and 52 other locations

Follicular lymphoma (FL), marginal zone lymphoma (MZL), and mantle cell lymphoma (MCL) are distinct histologic types of B-...

Active, not recruiting
Lymphoma, Non-Hodgkin
Drug: Rituximab
Drug: Lenalidomide

Phase 3

Celgene
Celgene

Trumbull, Connecticut, United States and 125 other locations

(R/R) chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma. However, single drug therapies have limitations, therefore, the current...

Enrolling
Follicular Lymphoma
Diffuse Large B Cell Lymphoma
Drug: DTRM-555

Phase 2

Zhejiang DTRM Biopharma

New Haven, Connecticut, United States and 7 other locations

B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). Classic...

Enrolling
Classic Follicular Lymphoma
Diffuse Large B-Cell Lymphoma
Drug: Epcoritamab

Phase 2

AbbVie
AbbVie

Port Jefferson Station, New York, United States and 49 other locations

The purpose of this study is to evaluate the safety and pharmacokinetics of eflapegrastim in pediatric participants with solid tumors or lymphoma...

Enrolling
Lymphoma
Solid Tumors
Drug: Chemotherapy
Drug: Eflapegrastim

Phase 2

Spectrum Pharmaceuticals
Spectrum Pharmaceuticals

Valhalla, New York, United States and 3 other locations

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems